Iksuda Therapeutics

Iksuda Therapeutics is a clinical-stage UK biotechnology company focused on developing class-leading antibody-drug conjugates (ADCs) for difficult-to-treat cancers. The company's differentiated approach centers on tumor-selective payload activation — designing each ADC with tailored components (linkers, payloads, bioconjugation methods) optimized for maximum anti-cancer efficacy and patient safety rather than applying a one-size-fits-all technology platform. Iksuda's growing clinical pipeline targets B-cell malignancies, HER2-positive cancers, and multiple solid tumors, and the company has introduced ProAlk, a first-in-class protein alkylating payload class with broad cross-tumor utility.